Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.34Last Year’s EPS
0.19Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 26, 2025
|% Change Since: 19.97%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and successful product launches, particularly with AGAMREE and FIRDAPSE, supported by a strong financial position and favorable patent resolution. However, there are challenges with anticipated revenue decline for FYCOMPA due to patent expiry, increased SG&A expenses, and expected impacts from the Inflation Reduction Act.Company Guidance
In the recent conference call for Catalyst Pharmaceuticals, the management team provided comprehensive guidance on their anticipated financial performance and strategic initiatives for 2025. The company reported a robust revenue growth of 23.5% for 2024, reaching $491.7 million, driven by their key products including FIRDAPSE and the newly launched AGAMREE. For 2025, Catalyst forecasts total revenues between $545 million and $565 million, with FIRDAPSE expected to contribute $355 million to $360 million, AGAMREE between $100 million and $110 million, and FYCOMPA $90 million to $95 million. They highlighted a strong cash position of $517.6 million and no debt, enabling continued investment in growth opportunities. The company also emphasized ongoing efforts to protect FIRDAPSE's market position through successful patent litigation outcomes and strategies to enhance AGAMREE's adoption. Additionally, Catalyst is actively exploring accretive business development opportunities in the rare disease space to further bolster their portfolio and sustain growth.Record Revenue Growth
Total revenues grew by 23.5% year-over-year to $491.7 million in 2024, exceeding previous guidance.
Successful Launch of AGAMREE
AGAMREE's full-year net product revenue reached $46 million, surpassing revised guidance, with strong adoption across DMD Centers of Excellence.
FIRDAPSE Sustained Growth
FIRDAPSE achieved a record revenue of $306 million in 2024, with 14 consecutive quarters of 15% or more growth year-over-year.
Strong Financial Position
The company ended 2024 with $517.6 million in cash and no debt, enhancing capacity for strategic growth opportunities.
Favorable Patent Resolution
Secured a favorable resolution to the Teva patent litigation, prohibiting generic entry until February 2035.
---
CPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 26, 2025 | $20.58 | $21.66 | +5.25% |
| Nov 06, 2024 | $22.71 | $23.25 | +2.38% |
| Aug 07, 2024 | $16.23 | $18.30 | +12.75% |
| May 08, 2024 | $14.72 | $15.65 | +6.32% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Catalyst Pharma (CPRX) report earnings?
Catalyst Pharma (CPRX) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Catalyst Pharma (CPRX) earnings time?
Catalyst Pharma (CPRX) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CPRX EPS forecast?
CPRX EPS forecast for the fiscal quarter 2025 (Q1) is 0.34.
---